100 related articles for article (PubMed ID: 21112549)
1. Photosensitizer Radachlorin®: Skin cancer PDT phase II clinical trials.
Kochneva EV; Filonenko EV; Vakulovskaya EG; Scherbakova EG; Seliverstov OV; Markichev NA; Reshetnickov AV
Photodiagnosis Photodyn Ther; 2010 Dec; 7(4):258-67. PubMed ID: 21112549
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients.
Bellnier DA; Greco WR; Loewen GM; Nava H; Oseroff AR; Pandey RK; Tsuchida T; Dougherty TJ
Cancer Res; 2003 Apr; 63(8):1806-13. PubMed ID: 12702566
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of Radachlorin-mediated photodynamic therapy in human hepatocellular carcinoma cells.
Mirzaei H; Djavid GE; Hadizadeh M; Jahanshiri-Moghadam M; Hajian P
J Photochem Photobiol B; 2015 Jan; 142():86-91. PubMed ID: 25528192
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo evaluation of Radachlorin(R) sensitizer for photodynamic therapy.
Douillard S; Olivier D; Patrice T
Photochem Photobiol Sci; 2009 Mar; 8(3):405-13. PubMed ID: 19255683
[TBL] [Abstract][Full Text] [Related]
5. Optimization of treatment parameters for Foscan-PDT of basal cell carcinomas.
Betz CS; Rauschning W; Stranadko EP; Riabov MV; Albrecht V; Nifantiev NE; Hopper C
Lasers Surg Med; 2008 Jul; 40(5):300-11. PubMed ID: 18563776
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and clinical effects of mono-L-aspartyl chlorin e6 (NPe6) photodynamic therapy in adult patients with primary or secondary cancer of the skin and mucosal surfaces.
Chan AL; Juarez M; Allen R; Volz W; Albertson T
Photodermatol Photoimmunol Photomed; 2005 Apr; 21(2):72-8. PubMed ID: 15752124
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic effects of a new photosensitizer for photodynamic therapy of early head and neck cancer in relation to tissue concentration.
Yoshida T; Tokashiki R; Ito H; Shimizu A; Nakamura K; Hiramatsu H; Tsukahara K; Shimizu S; Takata D; Okamoto I; Suzuki M
Auris Nasus Larynx; 2008 Dec; 35(4):545-51. PubMed ID: 18242905
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes following Foscan®-PDT of basal cell carcinomas.
Betz CS; Rauschning W; Stranadko EP; Riabov MV; Volgin VN; Albrecht V; Nifantiev NE; Hopper C
Lasers Surg Med; 2012 Sep; 44(7):533-40. PubMed ID: 22851213
[TBL] [Abstract][Full Text] [Related]
9. [Development of a novel photosensitizer, talaporfin sodium, for the photodynamic therapy (PDT)].
Tsukagoshi S;
Gan To Kagaku Ryoho; 2004 Jun; 31(6):979-85. PubMed ID: 15222124
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the effect of photoactivated disinfection with Radachlorin(®) against Streptococcus mutans (an in vitro study).
Fekrazad R; Bargrizan M; Sajadi S; Sajadi S
Photodiagnosis Photodyn Ther; 2011 Sep; 8(3):249-53. PubMed ID: 21864798
[TBL] [Abstract][Full Text] [Related]
11. Photodynamic effect of Radachlorin on nerve and glial cells.
Neginskaya MA; Berezhnaya EV; Rudkovskii MV; Demyanenko SV; Uzdensky AB
Photodiagnosis Photodyn Ther; 2014 Sep; 11(3):357-64. PubMed ID: 24981884
[TBL] [Abstract][Full Text] [Related]
12. Photodynamic therapy using mono-L-aspartyl chlorin e6 (Npe6) for the treatment of cutaneous disease: a Phase I clinical study.
Taber SW; Fingar VH; Coots CT; Wieman TJ
Clin Cancer Res; 1998 Nov; 4(11):2741-6. PubMed ID: 9829737
[TBL] [Abstract][Full Text] [Related]
13. Effects of chlorin-mediated photodynamic therapy combined with fluoropyrimidines in vitro and in a patient.
Zimmermann A; Walt H; Haller U; Baas P; Klein SD
Cancer Chemother Pharmacol; 2003 Feb; 51(2):147-54. PubMed ID: 12647016
[TBL] [Abstract][Full Text] [Related]
14. Chlorin e6 derivative radachlorin mainly accumulates in mitochondria, lysosome and endoplasmic reticulum and shows high affinity toward tumors in nude mice in photodynamic therapy.
Biswas R; Moon JH; Ahn JC
Photochem Photobiol; 2014; 90(5):1108-18. PubMed ID: 24666230
[TBL] [Abstract][Full Text] [Related]
15. Topical photodynamic therapy of murine non-melanoma skin carcinomas with aluminum phthalocyanine chloride and a diode laser: pharmacokinetics, tumor response and cosmetic outcomes.
Kyriazi M; Alexandratou E; Yova D; Rallis M; Trebst T
Photodermatol Photoimmunol Photomed; 2008 Apr; 24(2):87-94. PubMed ID: 18353089
[TBL] [Abstract][Full Text] [Related]
16. Photodynamic therapy by topical meso-tetraphenylporphinesulfonate tetrasodium salt administration in superficial basal cell carcinomas.
Santoro O; Bandieramonte G; Melloni E; Marchesini R; Zunino F; Lepera P; De Palo G
Cancer Res; 1990 Aug; 50(15):4501-3. PubMed ID: 2369729
[TBL] [Abstract][Full Text] [Related]
17. Skin necrosis due to photodynamic action of benzoporphyrin depends on circulating rather than tissue drug levels: implications for control of photodynamic therapy.
Lin GC; Tsoukas ML; Lee MS; González S; Vibhagool C; Anderson RR; Kollias N
Photochem Photobiol; 1998 Oct; 68(4):575-83. PubMed ID: 9796441
[TBL] [Abstract][Full Text] [Related]
18. DH-I-180-3-mediated photodynamic therapy: biodistribution and tumor vascular damage.
Lim DS; Ko SH; Lee CH; Ahn WS; Lee WY
Photochem Photobiol; 2006; 82(2):600-5. PubMed ID: 16613519
[TBL] [Abstract][Full Text] [Related]
19. Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma.
Campbell SM; Morton CA; Alyahya R; Horton S; Pye A; Curnow A
Br J Dermatol; 2008 Aug; 159(2):387-93. PubMed ID: 18544077
[TBL] [Abstract][Full Text] [Related]
20. The effect of Radachlorin® PDT in advanced NSCLC: a pilot study.
Ji W; Yoo JW; Bae EK; Lee JH; Choi CM
Photodiagnosis Photodyn Ther; 2013 May; 10(2):120-6. PubMed ID: 23769277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
